203 related articles for article (PubMed ID: 24862759)
1. Prolactin-induced protein is required for cell cycle progression in breast cancer.
Naderi A; Vanneste M
Neoplasia; 2014 Apr; 16(4):329-42.e1-14. PubMed ID: 24862759
[TBL] [Abstract][Full Text] [Related]
2. Prolactin-induced protein mediates cell invasion and regulates integrin signaling in estrogen receptor-negative breast cancer.
Naderi A; Meyer M
Breast Cancer Res; 2012 Jul; 14(4):R111. PubMed ID: 22817771
[TBL] [Abstract][Full Text] [Related]
3. Prolactin-induced protein (PIP) regulates proliferation of luminal A type breast cancer cells in an estrogen-independent manner.
Baniwal SK; Chimge NO; Jordan VC; Tripathy D; Frenkel B
PLoS One; 2014; 8(6):e62361. PubMed ID: 23755096
[TBL] [Abstract][Full Text] [Related]
4. Prolactin-induced protein in breast cancer.
Naderi A
Adv Exp Med Biol; 2015; 846():189-200. PubMed ID: 25472539
[TBL] [Abstract][Full Text] [Related]
5. Prolactin-Induced Protein regulates cell adhesion in breast cancer.
Vanneste M; Naderi A
Biochem Biophys Res Commun; 2015 Dec; 468(4):850-6. PubMed ID: 26585492
[TBL] [Abstract][Full Text] [Related]
6. A functional and regulatory network associated with PIP expression in human breast cancer.
Debily MA; Marhomy SE; Boulanger V; Eveno E; Mariage-Samson R; Camarca A; Auffray C; Piatier-Tonneau D; Imbeaud S
PLoS One; 2009; 4(3):e4696. PubMed ID: 19262752
[TBL] [Abstract][Full Text] [Related]
7. Identification of fibroblast growth factor-8b target genes associated with early and late cell cycle events in breast cancer cells.
Nilsson EM; Brokken LJ; Narvi E; Kallio MJ; Härkönen PL
Mol Cell Endocrinol; 2012 Jul; 358(1):104-15. PubMed ID: 22465097
[TBL] [Abstract][Full Text] [Related]
8. Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene signature associated with mitosis.
Bergamaschi A; Christensen BL; Katzenellenbogen BS
Breast Cancer Res; 2011 Jun; 13(3):R70. PubMed ID: 21707964
[TBL] [Abstract][Full Text] [Related]
9. Central spindle proteins and mitotic kinesins are direct transcriptional targets of MuvB, B-MYB and FOXM1 in breast cancer cell lines and are potential targets for therapy.
Wolter P; Hanselmann S; Pattschull G; Schruf E; Gaubatz S
Oncotarget; 2017 Feb; 8(7):11160-11172. PubMed ID: 28061449
[TBL] [Abstract][Full Text] [Related]
10. Prolactin Induced Protein (PIP) is a potential biomarker for early stage and malignant breast cancer.
Gangadharan A; Nyirenda T; Patel K; Jaimes-Delgadillo N; Coletta D; Tanaka T; Walland AC; Jameel Z; Vedantam S; Tang S; Mannion C; Lee GY; Goy A; Pecora A; Suh KS
Breast; 2018 Jun; 39():101-109. PubMed ID: 29656222
[TBL] [Abstract][Full Text] [Related]
11. Prolactin-induced protein (PIP) increases the sensitivity of breast cancer cells to drug-induced apoptosis.
Urbaniak A; Jablonska K; Suchanski J; Partynska A; Szymczak-Kulus K; Matkowski R; Maciejczyk A; Ugorski M; Dziegiel P
Sci Rep; 2023 Apr; 13(1):6574. PubMed ID: 37085653
[TBL] [Abstract][Full Text] [Related]
12. Isolation and sequencing of a cDNA clone for a prolactin-inducible protein (PIP). Regulation of PIP gene expression in the human breast cancer cell line, T-47D.
Murphy LC; Tsuyuki D; Myal Y; Shiu RP
J Biol Chem; 1987 Nov; 262(31):15236-41. PubMed ID: 3667631
[TBL] [Abstract][Full Text] [Related]
13. β1 Integrin is essential for fascin-mediated breast cancer stem cell function and disease progression.
Barnawi R; Al-Khaldi S; Colak D; Tulbah A; Al-Tweigeri T; Fallatah M; Monies D; Ghebeh H; Al-Alwan M
Int J Cancer; 2019 Aug; 145(3):830-841. PubMed ID: 30719702
[TBL] [Abstract][Full Text] [Related]
14. Pregnancy-associated plasma protein A regulates mitosis and is epigenetically silenced in breast cancer.
Loddo M; Andryszkiewicz J; Rodriguez-Acebes S; Stoeber K; Jones A; Dafou D; Apostolidou S; Wollenschlaeger A; Widschwendter M; Sainsbury R; Tudzarova S; Williams GH
J Pathol; 2014 Aug; 233(4):344-56. PubMed ID: 24931331
[TBL] [Abstract][Full Text] [Related]
15. FOXM1 transcriptionally regulates expression of integrin β1 in triple-negative breast cancer.
Hamurcu Z; Kahraman N; Ashour A; Ozpolat B
Breast Cancer Res Treat; 2017 Jun; 163(3):485-493. PubMed ID: 28361350
[TBL] [Abstract][Full Text] [Related]
16. RNAi-mediated silencing of Anxa2 inhibits breast cancer cell proliferation by downregulating cyclin D1 in STAT3-dependent pathway.
Zhang F; Wang Z; Yuan J; Wei X; Tian R; Niu R
Breast Cancer Res Treat; 2015 Sep; 153(2):263-75. PubMed ID: 26253946
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of lumican enhanced mitotic defects and aneuploidy in lung cancer cells.
Yang CT; Hsu PC; Chow SE
Cell Cycle; 2020 Jan; 19(1):97-108. PubMed ID: 31760859
[TBL] [Abstract][Full Text] [Related]
18. Additive effect of the AZGP1, PIP, S100A8 and UBE2C molecular biomarkers improves outcome prediction in breast carcinoma.
Parris TZ; Kovács A; Aziz L; Hajizadeh S; Nemes S; Semaan M; Forssell-Aronsson E; Karlsson P; Helou K
Int J Cancer; 2014 Apr; 134(7):1617-29. PubMed ID: 24114735
[TBL] [Abstract][Full Text] [Related]
19. The dual role of FOXF2 in regulation of DNA replication and the epithelial-mesenchymal transition in breast cancer progression.
Lo PK; Lee JS; Liang X; Sukumar S
Cell Signal; 2016 Oct; 28(10):1502-19. PubMed ID: 27377963
[TBL] [Abstract][Full Text] [Related]
20. miR-671-5p inhibits epithelial-to-mesenchymal transition by downregulating FOXM1 expression in breast cancer.
Tan X; Fu Y; Chen L; Lee W; Lai Y; Rezaei K; Tabbara S; Latham P; Teal CB; Man YG; Siegel RS; Brem RF; Fu SW
Oncotarget; 2016 Jan; 7(1):293-307. PubMed ID: 26588055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
